Drugs / B7-H3-targeting CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05241392 | Jan 2022 → Nov 2024 overdue | glioblastoma | Beijing Tiantan Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B7-H3-targeting CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05241392 ↗ |
| Known as | anti-B7-H3 autologous CAR-T cells | “Patients will be treated with anti-B7-H3 autologous CAR-T cells that are delivered into the intracranial tumor resection cavity or ventricular system using an Ommaya device.” NCT05241392 ↗ |
| Action | Deplete | “The CD70, CD47, CD80, CD86, B7H3, B7H4, PDL-1, TIGIT CAR-T cells and other CAR-T cells are discussed as an effective approach to deplete tumor cells expressing checkpoint proteins.” PMID 35468680 ↗ Apr 2022 |
| Modality | Cell therapy | “Chimeric Antigen Receptor-T (CAR-T) cell therapy” NCT05241392 ↗ |
| Route | Other | “delivered into the intracranial tumor resection cavity or ventricular system using an Ommaya device” NCT05241392 ↗ |